Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Prognostic Significance of Plasma Fibrinogen/Serum Albumin Ratio in the Postoperative Outcome of Pancreatic Ductal Adenocarcinoma

KOICHI TOMITA, SHIGETO OCHIAI, TAKAHIRO GUNJI, KOSUKE HIKITA, TOSHIMICHI KOBAYASHI, TORU SANO, NAOKAZU CHIBA and SHIGEYUKI KAWACHI
Anticancer Research December 2020, 40 (12) 7017-7023; DOI: https://doi.org/10.21873/anticanres.14727
KOICHI TOMITA
1Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIGETO OCHIAI
1Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAHIRO GUNJI
1Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOSUKE HIKITA
1Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIMICHI KOBAYASHI
1Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TORU SANO
1Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOKAZU CHIBA
1Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIGEYUKI KAWACHI
1Department of Digestive and Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: skawachi@tokyo-med.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Surgery is an important pancreatic ductal adenocarcinoma (PDAC) treatment; existing markers are inadequate prognostic indexes. We herein evaluated the utility of the FA score (fibrinogen/albumin ratio) for predicting PDAC postoperative outcomes. Patients and Methods: We analysed the data of 67 PDAC patients who underwent surgical resection. The relationship between postoperative outcomes and the FA score was investigated. Performance of the FA score was compared to that of other variables and prognostic indexes. Results: No patient with FA ≥130 survived >3 years, whereas all patients who survived longer had FA <130. The FA score was superior to all other indexes for predicting postoperative outcomes. Patients with FA ≥130 vs. <130 had significantly shorter overall and recurrence-free survival. Conclusion: The FA score is useful for predicting PDAC postoperative outcomes. Preoperatively, it may detect patients likely to have poor postoperative prognoses who may benefit from adjuvant or neoadjuvant therapy, thus improving outcomes.

Key Words:
  • FA score
  • fibrinogen
  • albumin
  • pancreatic ductal adenocarcinoma
  • surgical resection
  • prognostic index

Surgery is a potentially curative treatment for pancreatic ductal adenocarcinoma (PDAC) (1). Recently, the effectiveness of a multimodal approach that combines surgical resection with both adjuvant and neoadjuvant therapies has been reported in terms of survival (2). However, PDAC has a poorer prognosis than other cancers, although long-term survival has improved slightly (3). Furthermore, postoperative recurrences occur, even in the early stages. It is difficult to accurately evaluate the prognosis of PDAC based on the existing markers or indexes.

A better system is needed to evaluate prognosis before PDAC surgery to help detect high-risk patients and improve the indications for adjuvant and neoadjuvant therapy. Several prognostic factors utilizing systemic inflammation-based scores associated with cancer have been explored. According to previous reports, the C-reactive protein (CRP)/albumin ratio (CAR) (4), Glasgow Prognostic Score (GPS) (5), neutrophil/lymphocyte ratio (6), platelet/lymphocyte ratio (PLR) (7), and Prognostic Nutritional Index (PNI) have value as prognostic markers in PDAC or pancreatic cancer.

An additional index, the FA score, is the proportion of preoperative plasma fibrinogen to albumin. When a cancer progresses, the inflammatory response against it strengthens, resulting in an increase in fibrinogen and a decrease in albumin. Fibrinogen serves as a scaffold that binds growth factors, which in turn promote cellular responses associated with tumour cell adhesion, proliferation, and migration during cell growth and angiogenesis (8). Guo et al. (9) reported that fibrinogen levels were significantly higher in pancreatic cancer than in benign pancreatic tumours; moreover, elevated fibrinogen levels had a positive relationship with tumour stage and might be predictive of distant metastasis. Regarding albumin levels, malnutrition is common in patients with cancer, and serum albumin is a common indicator of nutritional status and a predictor of cancer survival (10). Thus, the FA score reflects the cancer severity. The FA score is a simple prognostic tool that has been studied in various malignant diseases of the lung, breast, oesophagus, gastric regions, liver, gallbladder, colorectal regions (including liver metastasis), and ovaries, as well as in sarcoma, leukaemia, and glioma. However, the role of the FA score as a prognostic marker in PDAC has not been previously investigated. In this study, we evaluated the utility of the preoperative FA score for predicting outcomes after surgical resection in patients with PDAC.

Patients and Methods

Ethics approval and informed consent. The procedures followed were in accordance with the ethical standards of the Institutional Review Board of Tokyo Medical University Hachioji Medical Center (T2020-0049) and with the Helsinki Declaration of 1975, as revised in 1983. Informed consent was obtained from all patients.

Patients. We retrospectively analysed clinical data of 111 patients who underwent surgical resection and had a postoperative histopathological diagnosis of PDAC at the Tokyo Medical University Hachioji Medical Center between July 2007 and May 2020. Patients with a histological diagnosis other than adenocarcinoma, including intraductal papillary mucinous carcinoma, neuroendocrine carcinoma, or benign tumour, were excluded. Patients with unresectable PDAC as per National Comprehensive Cancer Network (NCCN) guidelines (11) (distant metastasis or locally advanced tumour) were also excluded; only patients with resectable or borderline resectable PDA were included in our analysis. Additionally, we excluded patients who underwent neoadjuvant therapy (n=11) and those without preoperative fibrinogen or albumin assessments (n=33). We excluded neoadjuvant therapy patients because the proper evaluation timing of the FA score is unclear in these patients. After applying these criteria, 67 patients were eligible for inclusion.

Preoperative evaluation. A preoperative blood test was performed as close as possible to the time of surgery. All patients with obstructive jaundice and signs of cholangitis underwent biliary decompression before surgery. Endoscopic retrograde cholangiopancreatography was most often performed for bile reduction, and an endoscopic retrograde biliary drainage tube, metallic stent, or endoscopic naso-biliary drainage tube was inserted. No patients had signs of cholangitis at the time of surgery. Multiple prognostic indexes including the CAR (4), FA score, GPS (5), PLR (7), and PNI (12) were calculated based on blood tests. The FA score was calculated as follows: fibrinogen (mg/dl)/albumin (g/dl).

Surgical information. The resectability status (resectable and borderline resectable) was defined based on the NCCN guidelines (11). “Resectable” was defined as having no arterial superior mesenteric vein or portal vein contact, or as ≤180° contact without vein contour irregularity. “Borderline resectable” was defined as having more contact than a resectable tumour, but less than an unresectable tumour.

Pathological diagnosis. The pathological diagnosis was based on the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) guidelines (13), which include the tumour, nodes, and metastasis (TNM) classification, stage, and differentiation. Additionally, the microscopic lymphatic and venous invasion around the main tumour was evaluated in accordance with the AJCC/UICC guidelines. Microscopic histopathology including immunostaining (mainly D2-40 for lymphatic invasion and Elastica van Gieson for venous invasion) was used for diagnosis.

Postoperative course. The postoperative pancreatic fistula was graded according to the International Study Group on Pancreatic Fistula definition (14) as follows: grade A, transient fistula with no clinical impact; grade B, fistula requiring a change in management or an adjustment in the clinical pathway; grade C, fistula requiring a major change in clinical management or a deviation from the normal clinical pathway.

FA score evaluation. An FA score cut-off value was determined using a scatter plot of FA scores and postoperative survival. Two patient groups were defined based on whether the FA score was above or below the cut-off value, and patient characteristics were compared between the groups. The risk factors affecting overall survival (OS) and recurrence-free survival (RFS) were evaluated using multivariate analyses.

Statistical analysis. Continuous variables are expressed as the median and range (minimum to maximum); the Mann-Whitney U-test was used for comparisons between groups. Categorical variables are expressed as a count (%); they were compared using the chi-square test or Fisher’s exact test, as required. Univariate and multivariate analyses were performed using Cox proportional hazards regression analyses with forward-selection of the likelihood ratio. The prognosis was evaluated using the Kaplan-Meier method, and the statistical difference was evaluated using the log-rank test. Statistical tests were two-tailed, and significance was set at p<0.05. All statistical analyses were performed using IBM SPSS Statistics, version 26.0 (IBM Corp., Armonk, NY, USA).

Results

Patient characteristics. Patient characteristics and comparisons between the FA score groups are shown in Table I. The FA score cut-off value was defined as 130, as described below. Fibrinogen levels were significantly higher and albumin levels were significantly lower in the FA ≥130 group than in the FA <130 group. The white blood cell count and CRP levels were also significantly higher in the FA ≥130 group. Tumour marker levels were not significantly different between groups. Finally, all prognostic scores (CAR, FA score, GPS, PLR, and PNI) were significantly worse in the FA ≥130 group. In terms of pathological diagnosis, the most common AJCC/UICC stage was IIB, [38 patients (56.7%)]. No cases of stage IV disease were observed, because unresectable cases were excluded, and no patient had distant metastasis. Regarding prognosis, the median OS was 22.9 months and the median RFS was 11.7 months. No patient died due to surgery.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patient characteristics.

FA score cut-off calculation. The correlation between FA scores and postoperative survival is shown in Figure 1. Notably, no patient with an FA score ≥130 survived longer than 3 years, whereas all patients who survived beyond this time point had an FA score <130. Thus, the FA score cut-off value was defined as 130.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Scatter plot showing the relationship between the preoperative fibrinogen/albumin (FA) ratio score and postoperative survival. Circle: Surviving. Cross: Deceased. Vertical dotted line: FA score of 130. Horizontal dotted line: survival time of 3 years.

Risk factors for OS. Risk factors for OS were evaluated by univariate and multivariate analyses (Table II). Age, albumin, carcinoembryonic antigen (CEA), CA19-9 levels, FA scores, FA score ≥130, PNI, resection margin, AJCC/UICC stage, and venous invasion were found to be directly associated with reduced survival. In the multivariate analysis, CEA level, FA score ≥130, and venous invasion were identified as independent risk factors for reduced survival.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Univariate and multivariate analyses of clinicopathological factors for overall survival.

Comparison of OS. Figure 2a shows the comparison of OS between the FA <130 and ≥130 groups. Patients with an FA score ≥130 had a significantly shorter OS than those with an FA score <130 (p=0.005).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Kaplan-Meier curves of survival. (a) The overall survival in patients with a preoperative fibrinogen/albumin (FA) ratio score of <130 and ≥130. (b) The recurrence-free survival in patients with a preoperative fibrinogen/albumin (FA) ratio score of <130 and ≥130.

Comparison of RFS. Figure 2b shows the comparison of RFS between the FA <130 and ≥130 groups. The FA ≥130 group had a significantly shorter RFS than did the FA <130 group (p=0.015).

Discussion

The present study showed that the FA score is a good prognostic marker in patients with PDAC. An FA score ≥130 was an independent risk factor for postoperative OS and RFS, and patients with an FA score <130 had a significantly better prognosis than those with an FA score ≥130. The FA score can be a useful prognostic marker before surgery of PDAC. This score can help the preoperative detection of patients with poor prognosis who may benefit from adjuvant or neoadjuvant therapy.

The scatter plot showed that patients with a high FA score had a poor prognosis, whereas patients with a low FA score had a survival time varying from <1 year to >6 years. This suggests that a high presurgical FA score can help detect patients with reduced chances of postsurgical survival.

Although the GPS and PNI were also linked to survival in the univariate analysis, only the FA score remained significantly associated with survival in the multivariate analysis. The GPS is already known as a good prognostic marker for PDAC (15); a modified GPS, which has a minor change in CRP and albumin score with respect to the original GPS, has been described in the AJCC/UICC classification. However, our results suggested that the FA score performed better than did the GPS for predicting postoperative outcome in patients with PDAC.

Apart from preoperative blood tests, prognosis in pancreatic cancer depends on various factors like tumour size, histologic grade, vascular invasion, lymph node metastasis, and intrapancreatic perineural invasion. Herein, venous invasion was an independent risk factor for reduced survival, which is consistent with the findings of a previous report (16).

The present study had several limitations. First, it was performed in a single centre with a relatively small number of patients. Second, we did not evaluate changes in the FA ratio in relation to neoadjuvant therapy. Previous reports have suggested that variations in other parameters like the CA19-9 level and neutrophil/lymphocyte ratio after neoadjuvant therapy are associated with prognosis (6). Third, due to its retrospective nature, this study could not assess the role of the FA score in the decision-making process. A large, prospective, multicentre study including a more heterogeneous population is necessary to confirm the utility of this score for PDAC prognosis prediction when applying the proposed cut-off value.

Conclusion

Our findings suggest that the FA score can be a useful prognostic tool before surgical resection of PDAC. Although further studies will be needed, this score may help in the preoperative detection of patients likely to have a poor postoperative prognosis and may thus benefit from adjuvant or neoadjuvant therapy.

Footnotes

  • Authors’ Contributions

    K.T. developed the study concept and design, participated in the statistical analysis and data interpretation, and drafted the manuscript. All Authors contributed to data acquisition, critical manuscript revision, and final manuscript approval.

  • Conflicts of Interest

    The Authors declare no conflicts of interest in regard to this study.

  • Received October 6, 2020.
  • Revision received October 19, 2020.
  • Accepted October 22, 2020.
  • Copyright © 2020 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    1. Hartwig W,
    2. Werner J,
    3. Jäger D and
    4. Büchler MW
    : Improvement of surgical results for pancreatic cancer. Lancet Oncol 14(11): e476-e485, 2013. PMID: 24079875. DOI: 10.1016/S1470-2045(13)70172-4
    OpenUrlCrossRefPubMed
  2. ↵
    1. Traverso LW
    : Pancreatic cancer: surgery alone is not sufficient. Surg Endosc 20(2)Suppl 2: S446-S449, 2006. PMID: 16557419. DOI: 10.1007/s00464-006-0052-1
    OpenUrlCrossRefPubMed
  3. ↵
    1. Gemenetzis G,
    2. Groot VP,
    3. Blair AB,
    4. Laheru DA,
    5. Zheng L,
    6. Narang AK,
    7. Fishman EK,
    8. Hruban RH,
    9. Yu J,
    10. Burkhart RA,
    11. Cameron JL,
    12. Weiss MJ,
    13. Wolfgang CL and
    14. He J
    : Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg 270(2): 340-347, 2019. PMID: 29596120. DOI: 10.1097/SLA.0000000000002753
    OpenUrlCrossRefPubMed
  4. ↵
    1. Haruki K,
    2. Shiba H,
    3. Shirai Y,
    4. Horiuchi T,
    5. Iwase R,
    6. Fujiwara Y,
    7. Furukawa K,
    8. Misawa T and
    9. Yanaga K
    : The C-reactive protein to albumin ratio predicts long-term outcomes in patients with pancreatic cancer after pancreatic resection. World J Surg 40(9): 2254-2260, 2016. PMID: 26956901. DOI: 10.1007/s00268-016-3491-4
    OpenUrlCrossRefPubMed
  5. ↵
    1. Forrest LM,
    2. McMillan DC,
    3. McArdle CS and
    4. Dunlop DJ
    : Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89(6): 1028-1030, 2003. PMID: 12966420. DOI: 10.1038/sj.bjc.6601242
    OpenUrlCrossRefPubMed
  6. ↵
    1. Glazer ES,
    2. Rashid OM,
    3. Pimiento JM,
    4. Hodul PJ and
    5. Malafa MP
    : Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma. Surgery 160(5): 1288-1293, 2016. PMID: 27450715. DOI: 10.1016/j.surg.2016.04.039
    OpenUrlCrossRef
  7. ↵
    1. Smith RA,
    2. Bosonnet L,
    3. Raraty M,
    4. Sutton R,
    5. Neoptolemos JP,
    6. Campbell F and
    7. Ghaneh P
    : Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197(4): 466-472, 2009. PMID: 18639229. DOI: 10.1016/j.amjsurg.2007.12.057
    OpenUrlCrossRefPubMed
  8. ↵
    1. Simpson-Haidaris PJ and
    2. Rybarczyk B
    : Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci 936: 406-425, 2001. PMID: 11460495.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Guo Q,
    2. Zhang B,
    3. Dong X,
    4. Xie Q,
    5. Guo E,
    6. Huang H and
    7. Wu Y
    : Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor. Pancreas 38(3): e75-e79, 2009. PMID: 19276866. DOI: 10.1097/MPA.0b013e3181987d86
    OpenUrlCrossRefPubMed
  10. ↵
    1. Gupta D and
    2. Lis CG
    : Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9(1): 69, 2010. PMID: 21176210. DOI: 10.1186/1475-2891-9-69
    OpenUrlCrossRefPubMed
  11. ↵
    1. Tempero MA,
    2. Malafa MP,
    3. Al-Hawary M,
    4. Asbun H,
    5. Bain A,
    6. Behrman SW,
    7. Benson AB 3rd.,
    8. Binder E,
    9. Cardin DB,
    10. Cha C,
    11. Chiorean EG,
    12. Chung V,
    13. Czito B,
    14. Dillhoff M,
    15. Dotan E,
    16. Ferrone CR,
    17. Hardacre J,
    18. Hawkins WG,
    19. Herman J,
    20. Ko AH,
    21. Komanduri S,
    22. Koong A,
    23. LoConte N,
    24. Lowy AM,
    25. Moravek C,
    26. Nakakura EK,
    27. O’Reilly EM,
    28. Obando J,
    29. Reddy S,
    30. Scaife C,
    31. Thayer S,
    32. Weekes CD,
    33. Wolff RA,
    34. Wolpin BM,
    35. Burns J and
    36. Darlow S
    : Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(8): 1028-1061, 2017. PMID: 28784865. DOI: 10.6004/jnccn.2017.0131
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Kanda M,
    2. Fujii T,
    3. Kodera Y,
    4. Nagai S,
    5. Takeda S and
    6. Nakao A
    : Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 98(2): 268-274, 2011. PMID: 20960457. DOI: 10.1002/bjs.7305
    OpenUrlCrossRefPubMed
  13. ↵
    1. Brierley JD,
    2. Gospodarowicz MK and
    3. Wittekind C
    (eds.): TNM Classification of Malignant Tumours, 8th ed. Oxford, UK, John Wiley & Sons, 2017.
  14. ↵
    1. Bassi C,
    2. Dervenis C,
    3. Butturini G,
    4. Fingerhut A,
    5. Yeo C,
    6. Izbicki J,
    7. Neoptolemos J,
    8. Sarr M,
    9. Traverso W,
    10. Buchler M and International Study Group on Pancreatic Fistula Definition
    : Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138(1): 8-13, 2005. PMID: 16003309. DOI: 10.1016/j.surg.2005.05.001
    OpenUrlCrossRefPubMed
  15. ↵
    1. La Torre M,
    2. Nigri G,
    3. Cavallini M,
    4. Mercantini P,
    5. Ziparo V and
    6. Ramacciato G
    : The Glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol 19(9): 2917-2923, 2012. PMID: 22488099. DOI: 10.1245/s10434-012-2348-9
    OpenUrlCrossRefPubMed
  16. ↵
    1. Garcea G,
    2. Dennison AR,
    3. Ong SL,
    4. Pattenden CJ,
    5. Neal CP,
    6. Sutton CD,
    7. Mann CD and
    8. Berry DP
    : Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 33(7): 892-897, 2007. PMID: 17398060. DOI: 10.1016/j.ejso.2007.02.024
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 40 (12)
Anticancer Research
Vol. 40, Issue 12
December 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prognostic Significance of Plasma Fibrinogen/Serum Albumin Ratio in the Postoperative Outcome of Pancreatic Ductal Adenocarcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Prognostic Significance of Plasma Fibrinogen/Serum Albumin Ratio in the Postoperative Outcome of Pancreatic Ductal Adenocarcinoma
KOICHI TOMITA, SHIGETO OCHIAI, TAKAHIRO GUNJI, KOSUKE HIKITA, TOSHIMICHI KOBAYASHI, TORU SANO, NAOKAZU CHIBA, SHIGEYUKI KAWACHI
Anticancer Research Dec 2020, 40 (12) 7017-7023; DOI: 10.21873/anticanres.14727

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Prognostic Significance of Plasma Fibrinogen/Serum Albumin Ratio in the Postoperative Outcome of Pancreatic Ductal Adenocarcinoma
KOICHI TOMITA, SHIGETO OCHIAI, TAKAHIRO GUNJI, KOSUKE HIKITA, TOSHIMICHI KOBAYASHI, TORU SANO, NAOKAZU CHIBA, SHIGEYUKI KAWACHI
Anticancer Research Dec 2020, 40 (12) 7017-7023; DOI: 10.21873/anticanres.14727
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
  • Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study
  • Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series
Show more Clinical Studies

Similar Articles

Keywords

  • FA score
  • fibrinogen
  • Albumin
  • pancreatic ductal adenocarcinoma
  • surgical resection
  • prognostic index
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire